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 ABSTRACT 
Inhibition of the protein-protein interaction between B-cell lymphoma 6 (BCL6) and corepressors has 
been implicated as a therapeutic target in diffuse large B-cell lymphoma (DLBCL) cancers and profiling 
of potent and selective BCL6 inhibitors are critical to test this hypothesis.  We identified a pyrazolo[1,5-
a]pyrimidine series of BCL6 binders from a fragment screen in parallel with a virtual screen.  Using 
structure based drug design, binding affinity was increased 100,000-fold.  This involved displacing 
crystallographic water, forming new ligand-protein interactions and a macrocyclization to favor the 
bioactive conformation of the ligands.  Optimization for slow off-rate constant kinetics was conducted 
as well as improving selectivity against an off-target kinase, CK2.  Potency in a cellular BCL6 assay 
was further optimized to afford highly selective probe molecules.  Only weak anti-proliferative effects 
were observed across a number of DLBCL lines and a multiple myeloma cell line without a clear 
relationship to BCL6 potency.  As a result we conclude that the BCL6 hypothesis in DLBCL cancer 
remains unproven. 
 
  
 Introduction. 
B-cell lymphoma 6 (BCL6) is a transcriptional repressor required for germinal center (GC) formation and 
maintenance during the humoral immune response but also has been implicated to play a role in 
lymphomas derived from GC B-cells.  BCL6 was originally identified as a target of chromosomal 
translocations in diffuse large B-cell lymphoma (DLBCL) (~40%) and follicular lymphoma (5-10%) 
cancers.1  Furthermore, in gain-of-function and loss-of-function studies, transgenic IµHA-BCL6 mice 
developed lethal DLBCL-like tumors2 and BCL6 shRNA induced lethality in DLBCL cell lines,3 
respectively. Published studies from a BCL6 mutant knock-in mouse model provided insight on the 
physiological effects of targeting BCL6 but in the context of normal GC development.4 Small molecule 
BCL6 inhibitors based on a promiscuous inhibitor class5 and peptido-mimetic6 inhibitors have been 
reported to lead to an anti-proliferative phenotype in DLBCL.  Recently, a high affinity BCL6-binding 
peptide has been reported.7  BCL6 has been proposed as an attractive cancer therapeutic target8 but there 
is a need for potent and selective tools to improve understanding of the BCL6 inhibition phenotype in 
DLBCL.  A homodimer of the N-terminal Broad-Complex, Tramtrack and Bric a brac (BTB) domain of 
BCL6 forms an extended groove which acts as a binding site for the corepressors silencing mediator for 
retinoid or thyroid-hormone receptors (SMRT), nuclear receptor corepressor (NCOR) and BCL6 
corepressor (BCOR).9, 10  The resulting protein-protein interaction (PPI) leads to the repression of genes 
through which the survival and proliferation effects of GC B-cells is allowed to progress.  PPI inhibition 
provides a significant challenge within medicinal chemistry,11 potentially explaining the lack of BCL6 
inhibitors published to date.  In this manuscript we describe how we identified and optimized inhibitors 
of the PPI between BCL6 and its corepressors to assess the impact of such inhibition on the proliferation 
of DLBCL cell lines.  
  
Results and Discussion 
Our lead generation strategy followed two parallel workstreams.  Firstly, inspection of the structure of the 
BCL6 BTB domain homodimer in complex with the corepressors BCOR12 and SMRT13 revealed what 
we considered to be a druggable binding pocket along the binding groove.  In the case of SMRT binding, 
Ile1428 and His1426 sidechains occupied this pocket but these interactions did not seem to fill the entirety 
of the available space.  Thus, a virtual screen to identify compounds that could bind to this pocket was 
conducted.  The first step was to dock 3000 fragment-sized molecules with molecular weight less than 
250 Daltons (Schrödinger, Glide).  These were used to map out affinity interactions in the binding site.  
Several top-scoring fragment poses were identified and combined into a single ‘virtual molecule’ that was 
used to define the desired ligand shape and pharmacophore.  The next step was to use this for a shape 
based virtual screen (OpenEye, ROCS) of the AstraZeneca compound collection.  Approximately 8000 
compounds were selected from this virtual screening exercise for screening in a BCL6 fluorescence 
resonance energy transfer (FRET) affinity assay.  Despite numerous false positives, one hit from this 
screen, pyrazolo[1,5-a]pyrimidine 1 was confirmed to competitively displace SMRT peptide in a 2D 
NMR experiment, and had a FRET IC50 affinity of 61 μM (Figure 1).  Secondly, a surface plasmon 
resonance (SPR) affinity screen of about 3500 fragments identified pyrazolo[1,5-a]pyrimidine 2 with a 
Kd of of 689 μM which also competitively displaced SMRT peptide in a 2D NMR experiment.  Both 
initial hits 1 and 2 were crystallized with BCL6 BTB domain homodimer and found to occupy similar 
positions for the pyrazolo[1,5-a]pyrimidine bicyclic ring system deeply bound into the cleft formed 
between the BCL6 BTB domain homodimers (Figure 2). 
 
Figure 1. Initial hits from virtual and fragment screen  
 1 2
  
 
Figure 2. Overlay of crystal structures of 1 (green, PDB code 5N20) and 2 (turquoise, PDB code 5N1X) 
in complex with BCL6 BTB domain homodimer (selected residues shown from the former only). 
 
 
 Despite the weaker affinity of 2, it had a higher ligand efficiency14 (LE) of 0.26 than 1 (LE = 0.17).  
However, since the large di-substituted aryl group at the 5-position of 1 was not as buried as the rest of 
the molecule in the protein, this group could be removed to give 3 which attained affinity and LE in the 
same region as 2 (Table 1).   Inspection of the crystal structure of 2 revealed that Arg24 appeared to form 
a cation-π interaction with the 5-pyridyl group and thus we postulated that a less planar ring system with 
a carboxylic acid group at this position could bind with higher affinity through an ionic interaction. The 
non-planar pyrrolidine analogue 4 was inactive in FRET but addition of a carboxylic acid in 5 did achieve 
measurable binding affinity.  Likewise homologated acid 6 was measured with FRET affinity of 55 μM 
 and although the LE is less than 0.3, an alternative measure of compound quality, ligand lipophilicity 
efficiency (LLE)15 was significantly increased due to reduced lipophilicity.  Our aim in subsequent 
optimization was to increase FRET affinity while maintaining LE around 0.3 and LLE above 5. 
 
Table 1. Initial SAR exploration at R1. 
 
Cpd R1 
BCL6 FRET 
IC50 (μM)a,b 
LEc LLEd 
3 H 
>99 
[SPR Kd = 319] 
0.33e 2.4e 
4 
 
>99 - - 
5 
 
45 0.26 5.7 
6 
 
64 0.24 4.7 
aMean of at least 2 independent measurements unless otherwise stated. bpIC50 SEM <0.18.  cLE = 1.4*pIC50 (FRET)/heavy atom 
count.  dLLE = pIC50 (FRET)-logD7.4.  eusing SPR pKd instead of FRET pIC50. 
 
 Further inspection of the crystal structures of 1 and 2 in BCL6 revealed that the ligands only 
partially occupied the binding pocket (Figure 2).  No solvent molecules were resolved in the remainder 
of the pocket for these structures, therefore 3D-RISM solvent analysis16 (CCG, MOE) was used to predict 
and characterize the positions of solvent molecules within the site.  This analysis showed a network of 
unstable water molecules in the upper half of the pocket, one of which formed a hydrogen bond with the 
NH backbone of Glu115.  This water was predicted to have high occupancy (0.79) and low stability 
 (∆Gbind = 2.5 kcal/mol) suggesting that displacement would result in an increase in ligand affinity.  We 
rationalized that increasing the size of the 7-cyclopropylamino group and adding a hydrogen bond forming 
moiety to interact with Glu115 could increase affinity through both Van der Waals and hydrogen bonding 
interactions.  A bicyclic lactam group was selected to fulfill these criteria and resulted in 7 with a 150-
fold increase in binding affinity (Table 2).  The co-crystal structure of 7 and BCL6 revealed that the 
bicyclic lactam traversed the binding pocket and the lactam carbonyl formed a clear hydrogen bond with 
the Glu115 backbone NH as predicted (Figure 3).  The carboxylic acid of 7 was proximal to Arg24 but 
did not appear to have the most favorable directionality for an ionic interaction and the interaction 
appeared to be via a structural water molecule.  Consequently, the smaller alcohol 8 was prepared in the 
expectation that a less ionic but still polar hydrogen bonding interaction could be realized and indeed 
affinity was maintained at 0.37 μM.  The importance of either the acid in 7 or alcohol in 8 was confirmed 
by pyrrolidine 9 which lacked these groups and had approximately10-fold reduced affinity. 
 
Figure 3. Crystal structure of 7 (PDB code 5N21) in complex with BCL6 BTB domain homodimer 
 
 
Table 2. SAR for acyclic and macrocyclic lactam containing compounds 
  
Cpd R1 R2 
BCL6 
FRET 
IC50 (μM)a,b 
LEc /  
LLEd 
 
Cpd R1 / R2 
BCL6 
FRET 
IC50 (μM)a,b 
LEc /  
LLEd 
Affinity fold-
increase on 
macrocyclization 
7 
 
H 0.35 
0.28 
6.9 
 
10 
 
0.0017 
0.32 
9.1 
206 
8 
 
H 0.37 
0.30 
4.1 
 
11 
 
0.0029 
0.33 
6.4 
128 
     
 
12 
 
0.015 
0.32 
5.4 
193 
9 
 
H 2.9 
0.28 
2.9 
 
13 
 
0.21 
0.27 
5 
14 
     
 
14 
 
0.024 
0.31 
5.3 
121 
aMean of at least 2 independent measurements. bpIC50 SEM <0.27. cLE = 1.4*pIC50 (FRET)/heavy atom count.  dLLE = pIC50 (FRET)-
logD7.4. 
 
 The next SAR breakthrough in our structure based drug design (SBDD) approach was realized 
through a macrocyclization strategy.  The 3-position carbon within the pyrrolidine ring of 7 was measured 
to be 7 Å from the aryl carbon meta to the aniline when crystallized with BCL6. Only solvent, not protein, 
filled the space between these two atoms.  This, coupled with the fact that the bound conformation of 7 is 
 not the lowest energy conformation of the isolated ligand, suggested that joining these two atoms with a 
linker could force the bioactive conformation of binding to BCL6 to be a more prevalent conformation.  
A bis-ether linker of six atoms in length was modelled to bridge the desired space and macrocycles 10, 
11 and 12 were prepared as the cyclized equivalents of 7, 8 and 9 respectively.  Gratifyingly, in all three 
cases, greater than 100-fold increase in affinity was realized through macrocyclization (Table 2).  An 
additional SAR observation was that the (5S)-methanol substitution in 11 gave 5-fold affinity increase 
over 5H analogue 12. 
A crystal structure of 11 bound to BCL6 was obtained and a remarkably close overlay between 
the acyclic 7 and macrocyclic 11 was observed in what is presumed to be the bioactive conformation 
(Figure 4).  The atoms in common between 11 and 7 overlay almost perfectly (RMSD = 0.96Å), with the 
exception of the substituent alpha to the pyrrolidine N which has switched sides due to the geometry 
enforced by the macrocyclic linker.  The alcohol now forms hydrogen bonds to a structural water, Arg28 
and back onto a pyrimidine N of the ligand.  The linker is well-defined in the electron density and sits in 
a solvent-exposed region, on top of the protein surface, close to Tyr58, but making no polar interactions. 
 
Figure 4. Overlay of crystal structures of 11 (magenta, PDB code 5N1Z) and 7 (orange, PDB code 
5N21) in complex with BCL6 BTB domain homodimer   
 
 
 In order to evaluate the extent to which free molecules in solution are adopting the bioactive 
conformation, a NMR-conformational analysis study was conducted. This conformational analysis makes 
use of interproton distances derived from NOE based experiments17 and fits the NMR data to ensembles 
of conformers, selecting those that show the highest agreement with the experimental NMR.18 Following 
this approach, it was observed for compound 8 that the pyrrolidine hydrogens and the aromatic H from 
the pyrimidine presented broad signals in the 1H NMR at rt, indicating the presence of a slow-intermediate 
exchange equilibrium between conformers affecting that part of the molecule, whereas the lactam ring 
showed sharp signals pointing to a fast rotation of the ring in solution. By heating the NMR sample to 70 
°C, a fast exchange between conformations was achieved and all the NMR signals were sharpened up.  
NMR data for 8 was acquired at the latter temperature as it gave optimal spectra for the conformational 
analysis study (see supporting information). The analysis yielded two main conformations in solution 
(Figure 5) with a relative population of 60:40. The main conformation 8A shows a good overall overlay 
with the X-ray structure of 11 except for the orientation of the lactam ring, which is rotated 180 degrees 
with respect to the bioactive conformation of 11. The second conformer 8B presents the lactam ring in 
the bioactive conformation, but shows a rotation of the pyrrolidine group compared to the X-ray structure. 
Therefore, the flexibility of the lactam and pyrrolidine rings prevent 8 from fully adopting the bioactive 
conformation.  
 
Figure 5. NMR solution conformations and relative populations for compounds 8 and 11. The X-ray 
structure of 11 as obtained bound to BCL6 (in green) is shown for comparison.  
  
A similar NMR analysis was carried out for macrocycle 11. In this case, the 1H NMR at room 
temperature showed a pattern of signals and J-couplings indicative of a rigid linker and no experiments 
were needed at high temperature for the conformational study. Two main conformations were found to 
be populated in solution at a ratio 79:18. Both show a good agreement with the bioactive conformation of 
the same molecule (Figure 5), especially the most populated conformation 11A (79%) which shows a 
nearly perfect match with the X-ray structure, indicating that the molecule has already adopted in solution 
the bioactive conformation, hence explaining the 128-fold affinity increase on macrocyclization of 8 to 
11.  
It was expected that a variety of different linkers could enable the bioactive conformation to be 
obtained but that some linkers would have greater probability of achieving this.  In order to try to predict 
promising linker structures a method was developed to examine the relationship between molecule 
conformation and affinity.  There are various ways to computationally derive the conformational 
ensemble of a molecule.  Standard rule-based methods tend to perform poorly with large rings as they fail 
to properly sample different conformations of the macrocycle.19, 20  Instead, a hybrid simulated annealing 
 / large-scale low-mode sampling method (Macrocycle Conformational Sampling, Schrödinger) was 
performed.  To ensure comprehensive sampling, 10,000 simulated annealing runs were conducted, each 
with 10,000 sampling search steps and the RMSD threshold for duplicate removal set to 0.001.  All 
generated conformations were retained and sampling was assumed complete such that the conformational 
ensemble is representative of the real solution conformation of the molecule.  Superimposition of each 
conformation onto the known bioactive conformation of 7 (not including the linker) was conducted and 
the RMSD of each individual conformation from the known bioactive conformation was calculated.  The 
distribution of RMSD from bioactive for the entire conformational population was thus derived.  It should 
be expected that compounds with a high proportion of conformations close to the bioactive conformation 
will have higher affinity than compounds that with a lower proportion of such similar conformations. 
 This predictive relationship between conformation ensembles and affinity was examined for five 
representative compounds from the existing set (9, 11, 12) and new linkers (13 and 14).  For each 
compound, a distribution of RMSD values for the conformational ensemble was observed, with a 
tendency to show a higher proportion at lower RMSD for higher affinity compounds.  The fraction of the 
conformation population with RMSD < 0.5 Å to the bioactive was observed to have an approximately 
linear correlation with the affinity on a log scale (Figure 6).  Subsequently, we used this model to help 
prioritize further linker designs for synthesis.   
 
Figure 6. Plot of BCL6 FRET affinity as a function of conformation ensemble RMSD (a) where line is 
a linear fit, with depictions of RMSD distribution for compound 9 (b) and compound 11 (c) where line 
is a bimodal normal fit 
  
The amide linker 13 was predicted to have a lower fraction of conformational ensembles matching 
the bioactive conformation and indeed only resulted in a 14-fold affinity increase on macrocyclization.  
In contrast, the fully saturated linker 14 was predicted to have a higher fraction of conformational 
ensembles matching the bioactive conformation and resulted in a 121-fold affinity increase.  All these 
macrocycles met our desired LE and LLE criteria.  It is worth noting that the bis-allyl compound 15 
(Figure 7), which is the acyclic precursor to 11, had a FRET affinity of  0.15 μM, indicating that addition 
of alkyl groups alone does not generate an affinity increase unless they are joined to form a macrocycle. 
Furthermore 8 and 11 are isolipophilic (measured logD7.4 of 2.3 and 2.2 for 8 and 11 respectively) thus a 
change in lipophilicity is not causing the increased affinity on macrocyclization. 
 
Figure 7. Acyclic precursor to macrocycle 11  
15  
 
  
 In acyclic compounds such as 8, free rotation of the pyrrolidine allows the chiral alcohol group 
freedom to occupy multiple conformations.  Indeed, the enantiomer of 8 has a very similar binding affinity 
of 0.59 μM, indicating that either stereochemistry can adopt a conformation favourable to binding.  When 
converted to a macrocycle such as 11, the rotation of the pyrrolidine is restricted and the chiral alcohol 
occupies a limited range of conformations which would be expected to show different SAR.  
Consequently, we prepared a number of different chiral alcohol containing macrocycles to explore the 
effect on binding affinity for different positions of this group.  This was completed in a simpler system 
without the lactam (Table 3).  Unsubstituted pyrrolidine 16 is inactive (> 100 μM) in FRET affinity but 
addition of a chiral alcohol in 17 gives a measurable binding affinity of 24 μM.  Macrocycle 18 contains 
pyrrolidine with only the macrocycle linker as a substituent and has affinity of 2.3 μM, consistent with 
previous increases in affinity due to macrocyclization (>43-fold in this case).  Macrocycle 19 showed that 
(2R)-methanol substitution reduced affinity 3.5-fold and (5R)-methanol substitution in 20 further reduced 
affinity.  In contrast (5S)-methanol substitution in 21 increased affinity 6-fold which is a similar increase 
compared to that observed in the lactam analogues 11 and 12.  In an attempt to explain the origin of this 
increase, 3D-RISM solvent analysis was used to characterize solvent molecules.  Analysis of the protein 
structure with 7, which does not contain the methanol moiety, predicts a stable structural water adjacent 
to the pyrimidine N and forming a bridging interaction to Arg28 (occupancy = 0.71, ∆Gbind = -0.98).  The 
protein structure of 11 demonstrates that the (5S)-methanol group perfectly displaces this predicted water 
and replaces all these interactions, spanning both units of the BCL6 dimer, and thus provides an 
explanation for the observed increase in affinity. 
 
Table 3. SAR for acyclic and macrocyclic compounds exploring effect of methanol substitution 
  
Cpd R1 R2 
BCL6 FRET 
IC50 (μM)a,b 
 
Cpd R1 / R2 
BCL6 FRET 
IC50 (μM)a,b 
16 
 
H > 100 
 
18 
 
2.3 
    
 
19 
 
8.2 
17 
 
H 24 
 
20 
 
> 10 
    
 
21 
 
0.39 
aMean of at least 2 independent measurements. bpIC50 SEM <0.18. 
 
 
 In our attempts to improve binding affinity to BCL6, we monitored the kinetics of binding with 
the aim of identifying compounds that had longer residence times and thus gave potential for longer lasting 
effects in cellular assays.21   A selection of kinetic data is shown in Table 4 to illustrate our findings.  
Gratifyingly, the binding affinity from SPR correlated very well with the affinity measured in FRET (R2 
= 0.99).  As affinity was increased, the on and off-rate constants were not modulated equally (Figure 8).  
Addition of the lactam ring (purple arrow) gave a significant decrease in the off-rate constant and a smaller 
increase in on-rate constant.  The transformation from acyclic to macrocycle (green arrows) gave a 
 substantially greater decrease in off-rate constant compared to increase in on-rate constant.  Addition of 
the (5S)-methanol (or (5S)-acetic acid) to a macrocyclic compound gave a substantial decrease in off-rate 
constant (pink arrows).  Thus, the affinity increase observed on macrocyclization of 7 to 10 and 8 to 11 
can be understood as a combination of two factors.  Firstly, an on-rate constant increase due to a more 
rigid linker giving the preorganized binding conformation and secondly, the delivery of the (5S)-methanol 
or (5S)-acetic acid to a favorable position for multiple hydrogen bonding interactions hence giving an off-
rate constant decrease.  Consequently, for the remainder of our optimization, the lactam ring, macrocycle 
and (5S)-methanol were retained. 
 
Table 4. FRET affinity and binding kinetics for BCL6 of selected compounds 
Cpd 
BCL6 FRET 
IC50 (μM)a,b 
BCL6 SPR 
Kd (μM)a,c 
BCL6 SPR 
kon (M-1.s-1) a,d 
BCL6 SPR 
koff (s-1) a,e 
5 45 60f - - 
7 0.35 1.1f 705000 f 0.77 f 
8 0.37 0.50 865000 0.44 
10 0.0017 0.0034f 4430000 f 0.015 f 
11 0.0029 0.0065 1560000 0.0083 
12 0.015 0.022 5530000 0.14 
21 0.39 0.39 506000 0.24 
25 0.0015 0.0050f 3270000 f 0.016 f 
aMean of at least 2 independent measurements unless otherwise stated. bpIC50 SEM <0.12. cpKd SEM <0.06. dlogSEM <0.26. 
elogSEM <0.22. fn=1   
 
Figure 8. On and off-rate constants for compounds in Table 4.  Arrows connect matched molecular pairs: 
pink arrow indicates addition of (5S)-methanol or (5S)-acetic acid, green arrow indicates macrocyclization 
and purple arrow indicates addition of lactam ring. 
 
 
   
 
Our original virtual screening hit 1 originated from an AstraZeneca project targeting the kinase 
CK2.22  Thus we profiled our lead BCL6 macrocycle 11 across a panel of 126 kinases to understand kinase 
selectivity (see supporting information).  Since we had already performed significant optimization for 
BCL6, we anticipated that CK2 activity would have been reduced.  The only kinase to exhibit greater than 
60% inhibition at 1 μM across the panel was indeed CK2 and this translated into a CK2 IC50 of 0.64 μM 
(220-fold margin vs BCL6).  The original hit 1 had CK2 IC50 of 0.012 μM in the same assay, thus the 
CK2 activity had been reduced 50-fold.  However, since the pyrazolo[1,5-a]pyrimidine core of our BCL6 
binders had been common to a series of AstraZeneca CK2 inhibitors, we sought to further develop SAR 
against CK2.  A crystal structure of 11 bound to CK2 was obtained which showed that the aniline NH of 
11 formed a key hydrogen bond in both proteins (Figure 9).  In CK2, this interaction was with the hinge 
domain of the kinase (Val116) while for BCL6 a strong hydrogen bond to the carbonyl of Met51 was 
formed.  While structurally quite different the binding pockets of BCL6 and CK2 exhibit similar 
interactions and 11 shows very similar bound conformations in each case: both show polar interactions 
for the lactam group and for the (5S)-methanol group, underlining the potential difficulty in obtaining 
selectivity over CK2.   
 
 Figure 9. Crystal structures of 11 bound to BCL6 (a, PDB code 5N1Z) and CK2 (b, PDB code 5N1V) 
showing nearly identical binding modes.   
 
 
 
As the 3-cyano group appeared to form a key interaction with Asp175 (via a bridging water 
molecule) in CK2 with no equivalent interaction in BCL6, we probed the SAR at this position (Table 5).  
BCL6 affinity was highest for the 3-CN analogue 22 and when only a hydrogen was present at this position 
(23) BCL6 affinity was reduced 20-fold along with a loss of CK2 activity (>10 μM), as anticipated from 
structural analysis.  Changing the 3-CN to 3-Cl in 24 resulted in similar BCL6 affinity with 3.5-fold 
reduction in CK2 activity, presumably due to the 3-Cl being unable to make the water mediated polar 
interaction with Asp175 in CK2.  This led us to prefer the use of 3-Cl in subsequent analogues. 
 
Table 5. SAR exploration at R3. 
 
(a) (b) 
 Cpd R3 
BCL6 FRET 
IC50 (μM)a,b 
CK2 
IC50 (μM)a,c 
BCL6: CK2 
selectivity 
22 CN 0.0024 0.40 166 
23 H 0.055 >10 >181 
24 Cl 0.0033 1.4 424 
aMean of at least 2 independent measurements. bpIC50 SEM <0.22. cpIC50 SEM <0.14. 
 
Finally, the SAR around substitution of the lactam nitrogen (R4) was explored (Table 6).  With 
high affinity BCL6 binders, we were able to demonstrate activity in a BCL6 cell reporter assay and 
develop cellular SAR. The unsubstituted analogue 25 exhibited high BCL6 affinity, weak CK2 activity 
and modest BCL6 cell activity (4.1 μM). The measured intrinsic permeability of 25 in a Caco-2 assay was 
measured to be high (Papp = 46 x 10
-6cm·s-1) and in a bidirectional Caco-2 efflux assay the efflux ratio 
was measured to be 1.4.  Aqueous solubility of 25 was measured as 31 μM thus it was difficult to attribute 
a physicochemical reason for the large drop-off from binding affinity to cellular activity against BCL6.  
We believed it was likely that although the FRET binding affinity is a direct measure of affinity to the 
BCL6 BTB domain homodimer, this assay may not be fully representative of the binding of compound 
to BCL6 within a complex cellular environment in the presence of endogenous corepressors.  
Consequently, although we wished to maintain high FRET affinity, our focus was to develop SAR and 
increased potency against the BCL6 cell reporter assay. 
Lipophilic groups of increasing size at R4 maintained high affinity for BCL6 while maintaining 
CK2 activity above 1 μM (26 -28).  Notably, the largest of these, containing the di-fluorocyclobutyl group 
(28), gave a 10-fold increase in BCL6 cell potency.  Analysis of all BCL6 crystal structures could not 
rationalize a binding interaction between the di-fluorocyclobutyl group and protein as it would be 
expected to occupy a solvent accessible space.  Encouraged by the cell potency of this group, carboxylic 
acid 29 with the same R4 was prepared but BCL6 affinity and cell potency decreased 3-fold and 6-fold 
respectively and CK2 activity was increased 13-fold.  The acid side-chain of Glu115 exists on the BCL6 
homodimer surface and compound 30 with a basic sidechain was designed to make an interaction with 
 this acid.  High BCL6 affinity was observed for 30 but the cell activity remained above 1 μM.  Thus we 
returned to lipophilic R4 groups and a range of benzylic compounds (31-36) were prepared.  All these 
benzyl compounds had similar BCL6 binding affinity of around 0.01 μM and showed no activity against 
CK2 when a 3-Cl substituent was employed.  Comparison of 3-Cl 32 with 3-CN 33 highlighted that even 
in these optimized compounds the 3-CN substituent still produced some weak CK2 activity.  Sub-
micromolar BCL6 cell potency with SAR was observed for all these benzyl compounds irrespective of 
the 3-substituent.  Methoxy substitution at the meta-benzyl position in 32 displayed 0.10 μM cell potency 
and methyl substitution at the ortho-benzyl position in 34 gave 0.087 μM cell potency.  Moving the methyl 
to the para-benzyl position in 35 reduced cell potency 10-fold to 0.83 μM.  Aza-incorporation in pyridine 
36 was tolerated and afforded 0.43 μM cell potency.  For comparison, FX1, the most potent BCL6 small 
molecule inhibitor reported to date has BCL6 binding affinity of 37 μM in our FRET assay and a best 
measured cell potency of 26 μM (close to the 30 μM top concentration used) which is consistent with 
reported data.5   
 
Table 6. SAR exploration at R4. 
2925-28, 30-36 FX1  
Cpd R3 R4 
BCL6 FRET 
IC50 (μM)a,b 
CK2  
IC50 (μM)a,c 
BCL6 cell  
IC50 (μM)a,d 
25 Cl H 0.0015 7.3 4.1 
26 Cl Me 0.0049 7.0 6.1 
27 Cl cPrCH2 0.036 2.2 5 
28 Cl 3,3-diFcBu CH2 0.0050 2.1 0.48 
 29 - - 0.016 0.16 3.2 
30 Cl 
morpholino-
CH2CH2CH2 
0.00087 5.9 1.1 
31 Cl Bn 0.011 >10 0.20 
32 Cl m-MeOBn 0.012 >10 0.10 
33 CN m-MeOBn 0.011 1.2 0.14 
34 Cl o-MeBn 0.013 >10 0.087 
35 Cl p-MeBn 0.029 >10 0.83 
36 Cl 4-pyridyl-CH2 0.0099 >10 0.43 
FX1 - - 49 0.69 >30e 
aMean of at least 2 independent measurements. bpIC50 SEM <0.26. cpIC50 SEM <0.18. dpIC50 SEM <0.25. ean effect was 
observed during 3 independent measurements with  IC50 = 26 μM obtained on one occasion and >30 μM on two other occasions. 
 
 All compounds tested in the BCL6 cell reporter assay were also tested in a PLZF cell reporter 
assay to rule out pan-BTB domain protein activity.  All compounds were inactive (>30 μM) in the PLZF 
assay.  Compound 31 was selected from our set of potent cell active BCL6 inhibitors and profiled across 
a panel of 398 kinases screened at 1 μM at ThermoFisher.  No activity above 70% was detected for any 
kinase (see supporting information).  Furthermore, in vitro pharmacological profiling23 of 31 against a 
panel of over 30 diverse targets was conducted and exhibited a good selectivity profile (see supporting 
information) with only two targets showing activity below 1 μM (GABA receptor, Ki = 0.25 μM; 5-
hydroxytryptamine receptor 1B, EC50 = 0.57 μM).  This profiling led us to conclude that we had achieved  
our aim to develop highly selective cell potent BCL6 inhibitors.  
 
Antiproliferative activity 
DLBCL cell lines have been classified as BCL6 dependent or independent on the basis of whether they 
are affected by BCL6 inhibition or knockdown.3, 5, 6   We sought to examine the antiproliferative activity 
of our BCL6 inhibitors in a range of DLBCL cell lines (both GCB and ABC subtypes) based on this 
classification of BCL6 dependent (e.g. OCI-Ly1, SUDHL-4, OCI-Ly3, SUDHL2, U-2932, OCI-Ly10, 
TMD8) and BCL6 independent (e.g. Karpas 422, OCI-Ly19) lines (Table 7).  In addition, we included a 
 multiple myeloma (MM) cell line as a cell line that we expected to be insensitive to BCL6 inhibition given 
that MM lines derive from post GC-B cells and generally express weak or undetectable levels of BCL6.24  
 FX1 displayed weak antiproliferative activity across the entirety of our cell panel.  We hoped that as we 
tested increasingly more potent and selective BCL6 inhibitors, a clear pattern of inhibition dependent on 
sensitivity to BCL6 would emerge.  However, as illustrated in Figure 10, weak antiproliferative activity 
was consistently observed across the entirety of the cell panel.  Those DLBCL cell lines previously 
defined as BCL6 sensitive did not show any difference from those defined as insensitive and the pattern 
of activity in the MM line was also similar.  This leads us to conclude that the inhibition of BCL6 is either 
not relevant for proliferation of these DLBCL lines or that the effect is too weak to be of significance.  
Consequently, we conclude that the BCL6 hypothesis as a means of treatment for DLBCL is still unproven 
and we have elected not to progress this series of BCL6 inhibitors further into development. 
  
Table 7. BCL6 cell potency and cell proliferation data 
Cpd 
BCL6 
cell 
pIC50a,b 
GCB 
Krpas422 
pGI50a,c 
GCB 
OCI-Ly1 
pGI50a,d 
GCB 
SUDHL4 
pGI50a,e 
GCB 
OCI-Ly19 
pGI50a,f 
ABC 
OCI-Ly3 
pGI50a,g 
ABC 
SUDHL2 
pGI50a,h 
ABC 
U-2932 
pGI50a,i 
ABC 
OCI-Ly10 
pGI50a,j 
ABC 
TMD8 
pGI50a,k 
MM 
AMO-1 
pGI50a,l 
11 5.7 5.1 5.0 5.1 5.2 5.4 5.5 5.2 5.3 5.1 4.8m 
14 4.8 5.1 5.1 5.0 5.1 5.4 5.0 5.0 5.1 5.3 5.0m 
22 5.2 4.7 4.6 4.6 4.8 4.9 4.9 4.8 5.0 4.8 4.7 
23 5.0 4.9 4.9 4.7 4.9 4.8 5.0 4.8 4.9 5.0 4.9m 
24 5.4 5.3 5.2 5.0 5.8 5.5 5.4 5.3 5.6 5.5 5.4m 
25 5.4 5.3 5.4 5.2 5.7 5.7 5.4 5.6 5.8 5.6 5.5m 
26 5.2 5.3 5.2 5.2 5.3 5.2 5.5 5.3 5.2 5.4 5.3m 
27 5.3 <4.5 <4.5 <4.5 4.8 <4.5 4.7 5.0 4.7 4.6 <4.5m 
28 6.3 5.0 5.1 5.0 5.2 4.9 5.1 5.2 5.1 5.0 4.6 
29 5.5 4.7 4.8 4.8 5.0 4.7 4.7 4.8 4.8 4.8 4.5 
30 5.9 4.9 5.0 4.9 5.1 5.0 5.0 5.0 5.1 5.0 4.9 
31 6.7 4.6 4.9 4.8 5.0m 4.9m 5.0m 5.1m 5m 5.0 4.6 
32 7.0 4.6 5.2 4.5m 5.0 <4.5 5.2 4.8 5.2 4.7 4.8 
33 6.9 5.3 5.5 5.2 5.3 5.2 5.6 5.4 5.4 5.4 5.0 
34 7.1 <4.5 5.0 5.2 5.0 4.8 5.2 5.0 5.0 4.7 4.6 
35 6.1 <4.5 5.1 4.7 5.0 4.8 5.2 5.0 4.9 4.8 4.7 
36 6.4 4.9 5.0 5.0 4.9 4.9 5.1 5.0 5.0 5.0 4.7 
 FX1 <4.5 4.9 4.7 5.0 5.0 4.7 4.9 4.9 4.9 5.0 4.7 
aMean of at least 2 independent measurements unless otherwise stated. bpIC50 SEM <0.25. cpIC50 SEM <0.24. dpIC50 SEM 
<0.18. epIC50 SEM <0.25. fpIC50 SEM <0.35. gpIC50 SEM <0.43. hpIC50 SEM <0.25. ipIC50 SEM <0.27. jpIC50 SEM <0.14. 
kpIC50 SEM <0.25. lpIC50 SEM <0.15. mn=1   
  
Figure 10. Plot of proliferation pGI50 variation with BCL6 cell pIC50 for compounds in Table 7 (FX1 is 
marked by a diamond, AstraZeneca compounds by circles and each compound is a different colour) 
 
 
Synthesis 
Aromatic nucleophilic substitution of the corresponding 5,7-dichloropyrazolopyrimidines with nitrogen 
nucleophiles was a key reaction for efficient assembly of all BCL6 inhibitors prepared during this work. 
For example, in a simple one-pot procedure, dichloropyrazolopyrimidine 37 reacted first with 6-amino-
3,4-dihydroquinolin-2(1H)-one then (S)-2-(pyrrolidin-2-yl)acetic acid to afford 7 in 41% yield (Scheme 
1). 
 
Scheme 1. Synthesis of acyclic pyrazolo[1,5-a]pyrimidinesa 
 3 4-9, 16, 17 
R6 = H, CO
2
H, CH
2
CO
2
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2
OH
R5 = c-Pr, Ph, a, b c or d, e
37
 
a
Reagents and conditions: (a) c-PrNH2, EtOH, 99%; (b) Pd/C, H2, EtOAc, 53%; (c) c-PrNH2 or PhNH2 or 6-amino-3,4-
dihydroquinolin-2(1H)-one, DIPEA, NMP, rt-100 ºC, then pyrrolidine-R6, μw, 65-130 ºC, 25-64%; (d) 6-amino-3,4-
dihydroquinolin-2(1H)-one, EtOH, 80 ºC, 91%; (e) (S) or (R)-prolinol, DIPEA, NMP, 80 ºC, 65-67%. 
 
Initially, we utilized the ring-closure metathesis (RCM) reaction between two allyloxy groups to 
form the large rings of macrocyclic inhibitors. For instance, the bicyclic aniline 39 reacted with the 
dichloropyrazolopyrimidine 37 and then with 3-(allyloxy)pyrrolidine to afford bis-allyloxy derivative 40 
which underwent RCM in the presence of Grubbs II catalyst to afford the macrocycle 12 (Scheme 2). The 
acid containing analogue 10 was prepared in a similar fashion from 39 and the disubstituted pyrrolidine 
42.  
 
Scheme 2. Synthesis of macrocycles using RCM routea 
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a
Reagents and conditions: (a) 2M K2CO3, MeOH, rt; (b) allyl bromide, K2CO3, DMF, rt; (c) Zn, AcOH, 60 ºC, 79% (3 steps); 
(d) 37, DIPEA, EtOH, 100 ºC, then (S)-3-(allyloxy)pyrrolidine hydrochloride, 100 ºC, 54%; (e) Grubbs II catalyst, DCM, 40 
ºC, 40%; (f) (Boc)2O, Et3N, DCM, rt, 49%; (g) DIAD, PPh3, 4-nitrobenzoic acid, THF, 0 ºC; (h) NaOH, MeOH, THF, rt, 67% 
(2 steps); (i) NaOH, MeOH, rt, 91%; (j) allyl bromide, NaH, THF/DMSO, rt, 58%; (k) TMSCHN2, PhMe, MeOH, rt, 68%; (l) 
HCl in dioxane, rt, 95%; (m) 39, 37, DIPEA, EtOH, 80 ºC, 74%; (n) 42, DIPEA, EtOH, 130 ºC, 85%; (o) Grubbs II catalyst, 
DCM, 40 ºC, 41%; (p) LiOH, H2O, MeOH, 40 ºC, 59%. 
 
Alternatively, we developed a novel strategy for the construction of diverse macrocyclic motifs. 
Our new approach was based on the double aromatic nucleophilic substitution reaction between pre-
assembled masked di-nucleophiles (e.g. 47) with corresponding heterocyclic di-electrophiles (37 or 48, 
Scheme 3). In this sequence the nitro group in 47 was reduced to the corresponding aniline which 
subsequently reacted with 5,7-dichloropyrazolo[1,5-a]pyrimidine-3-carbonitrile (37)  by displacing the 
more reactive chlorine at the 7-position. Both trityl and Boc protecting groups were removed 
simultaneously under acidic conditions and the resulting secondary amine displaced the chlorine at the 5-
position under thermal conditions to afford the macrocycle 11 in 46% overall yield.  Using this double 
SNAr attack (SNACK) strategy the macrocyclic linker could be easily varied and a number of diverse 
 macrocycles including 25, 13, 14 and 22-24 were obtained by cyclizing corresponding masked di-
nucleophiles 47, 50, 53 and 56, respectively (Scheme 3).  
 
Scheme 3. Synthesis of macrocycles using double SNAr (SNACK) route
a 
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a
Reagents and conditions: (a) K2CO3, MeOH, rt, 95%; (b) TrCl, Et3N, DMAPcat, DCM, rt, 66%; (c) (E)-1,4-dibromobut-2-ene, 
n-Bu4HSO4 cat, PhMe, NaOHaq, rt, 65%; (d) K2CO3, DMF, 80 ºC, 96%; (e) Fe, NH4Cl, EtOH, H2O, 60 ºC, 96%; (f)  37 or 48, 
DIPEA, EtOH, 60 ºC; (g) TFA, DCM, rt; (h) DIPEA, n-BuOH, μw, 130 ºC, 46% for 11, 7% for 25 (3 steps);  (i) tert-butyl (2-
 hydroxyethyl)carbamate, DIAD, Ph3P, DCM, rt, 88%; (j) HCl, 1,4-dioxane, MeOH, 84%; (k) (R)-2-(1-(tert-
butoxycarbonyl)pyrrolidin-2-yl)acetic acid, DIPEA, HATU, DMF, 81%; (l) Pd/C, H2, MeOH, quant.; (m) 37, DIPEA, EtOH, 
70 ºC; (n) HCl, 1,4-dioxane, rt; (o) DIPEA, n-BuOH, μw, 120 ºC, 11% (3 steps);  (p) 1,4-dibromobutane, n-Bu4HSO4 cat, 
PhMe, NaOHaq, rt, 88%; (q) 38, K2CO3, DMF, 70 ºC, 48%; (r) Pd/C, 1-methylcyclohexa-1,4-diene, EtOH, 80 ºC, 100%; (s)  
37, DIPEA, EtOH, 80 ºC; (t) HCl, 1,4-dioxane, rt; (u) DIPEA, n-BuOH, μw, 120 ºC, 42% (3 steps); (v) ) TrCl, Et3N, DMAPcat, 
DCM rt, 66%; (w) 1,4-dibromobutane, n-Bu4HSO4 cat, PhMe, NaOHaq, rt, 93%; (x) 44, K2CO3, DMF, 80 ºC, 99%; (y) Pd/C, 
HCOONH4, EtOH, 80 ºC, 100%; (z)  37 or 57 or 48, DIPEA, EtOH, 80 ºC; (aa) HCl, 1,4-dioxane, rt; (ab) DIPEA, n-BuOH, 
μw, 120-150 ºC, 14-28% (3 steps). 
 
The substituent on the lactam nitrogen was introduced by alkylation of the corresponding 6-nitro 
bicyclic lactams (e.g. 47) with alkyl/benzyl bromides or iodides (Scheme 4). R4 as a pyridin-4-ylmethyl 
was introduced using Mitsunobu reaction of 47 with pyridin-4-ylmethanol. The macrocycle 29 was 
prepared from 60 employing RCM. Other analogues having a substituent on the lactam nitrogen (26-28 
and 30-36) were synthesized from the aniline 62 using our preferred SNACK approach. 
 
Scheme 4. Synthesis of R4 substituted macrocyclesa 
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a
Reagents and conditions:   (a) 3-(bromomethyl)-1,1-difluorocyclobutane, Cs2CO3, DMF, 80 ºC, 82%; (b) Fe, EtOH, H2O, 80 
ºC, 92%; (c) 48, DIPEA, EtOH, 80 ºC, 82%; (d) 42, DIPEA, EtOH, 130 ºC; (e) TMSCHN2, PhMe, MeOH rt, 21% (2 steps); 
(f) Grubbs II catalyst, DCM, 40 ºC, 35%; (g) LiOH, H2O, MeOH, 40 ºC, 54%; (h) R4Br or R4I, Cs2CO3, DMF, rt-80 ºC, 59-
93%; (i) pyridin-4-ylmethanol, 2-(tributyl-l5-phosphanylidene)acetonitrile, THF, μw, 150 ºC, 36%; (j) morpholine, i-PrOH, 
μw, 100 ºC, 97%; (k) Fe, NH4Cl, THF, MeOH, H2O, reflux, 54-100%; (l) 37 or 48, DIPEA, EtOH, 60-80 ºC; (m) HCl, 1,4-
dioxane, rt or TFA, DCM, rt; (n) DIPEA, n-BuOH, μw, 130-140 ºC, 13-82% (3 steps). 
 
Conclusion 
Starting with a fragment screen and virtual screen we identified weak hits targeting the PPI interaction 
between BCL6 and its corepressors.  Using SBDD, binding affinity was increased 100,000-fold.  This 
involved displacing binding site water, forming new ligand-protein interactions and a macrocyclization 
to favour the bioactive conformation of the ligands.  Optimization for slow-off rate constant kinetics was 
conducted as well as improving selectivity against an off-target kinase, CK2.  Potency in a cellular BCL6 
assay was further optimized to afford highly selective probe molecules.  Anti-proliferative activity was 
assessed across a number of DLBCL lines, and a MM cell line.  Despite increasing BCL6 potency, only 
 weak anti-proliferative effects were observed across the cellular panel with no clear relationship to BCL6 
sensitive or insensitive lines.  As a result, we conclude that the BCL6 hypothesis as a means of treatment 
for DLBCL remains unproven. 
 
Experimental Section 
 General. All solvents and chemicals used were reagent grade. Anhydrous solvents THF, DCM 
and DMF were purchased from Aldrich. Flash column chromatography was carried out using prepacked 
silica cartridges (from 4 g up to 330 g) from RedisepTM or Silicycle and eluted using an Isco Companion 
system. Purity and characterization of compounds were established by a combination of liquid 
chromatography-mass spectroscopy (LC-MS), gas chromatography-mass spectroscopy (GC-MS) and 
NMR analytical techniques and was >95% for all test compounds. 1H NMR were recorded on a Varian 
INOVA (600 MHz), Varian Gemini 2000 (300 MHz) or Bruker Avance DPX400 (400 MHz) and were 
determined in CDCl3, DMSO-d6 or MeOH-d4. Chemical shifts are reported in ppm relative to TMS (0.00 
ppm) or solvent peaks as the internal reference. Splitting patterns are indicated as follows: s, singlet; d, 
doublet; t, triplet; m, multiplet; br, broad peak.  Elevated temperatures were used where necessary to 
sharpen broad NMR peaks due to rotamers and the temperature used is noted for such compounds.  Merck 
precoated TLC plates (silica gel 60 F254, 0.25 mm, art. 5715) were used for TLC analysis. 
 
Synthesis of representative key examples (11, 31, 32 and 34)  
 
6-Nitro-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl acetate (38) 
Fuming nitric acid (180 mL, 3.8 mol) was added slowly to a suspension of 2-oxo-1,2,3,4-
tetrahydroquinolin-8-yl acetate (78 g, 0.38 mol) in AcOH (570 mL) cooled in a water bath. The addition 
was controlled to keep the internal temperature below 35 °C. After addition was complete, the solution 
was stirred (a precipitate started to form after 5 min) for a further 25 min. The suspension was poured into 
ice water (1.56 L) and stirred for 20 min. The precipitate was collected by filtration, washed with water 
 (400 mL), diethylether (200 mL) and dried under vacuum to afford the title compound (90 g, 95%) as a 
cream solid. 1H NMR (400 MHz, DMSO-d6) δ 2.32 (s, 3H), 2.52-2.57 (m, 2H), 3.04-3.09 (m, 2H), 7.97 
(d, J = 2.5 Hz, 1H), 8.02-8.05 (m, 1H), 10.53 (br s, 1H); MS (ESI) [M-H]- m/z 249. 
8-Hydroxy-6-nitro-3,4-dihydroquinolin-2(1H)-one (44) 
A solution of K2CO3 (2M in water) (216 mL, 431 mmol) was added to 38 (90 g, 360 mmol) in MeOH (1 
L) and the resulting mixture was stirred for 10 min. The mixture was diluted with water (1 L), acidified 
to pH 1 with 2M HCl and the resulting solid was collected by filtration, washed with water and dried 
under vacuum to afford the title compound (71 g, 95%) as a yellow solid.  1H NMR (500 MHz, DMSO-
d6) δ 2.51-2.54 (m, 2H), 2.94-3.01 (m, 2H), 7.52 (d, J = 2.5 Hz, 1H), 7.63-7.69 (m, 1H), 9.51 (s, 1H), 
10.72 (s, 1H); 13C NMR (101 MHz, DMSO-d6 ) δ 25.07, 30.44, 108.59, 114.87, 125.45, 133.47, 141.92, 
144.32, 170.23; HRMS (ES+) for C9H8N2O4 (M+H)
+: calcd, 209.0557; found, 209.0558 
 (2S,4S)-tert-Butyl 4-hydroxy-2-((trityloxy)methyl)pyrrolidine-1-carboxylate 
DMAP (1.57 g, 12.9 mmol) was added to a stirred solution of (2S,4S)-tert-butyl 4-hydroxy-2-
(hydroxymethyl)pyrrolidine-1-carboxylate (45) (35 g, 129 mmol), trityl chloride (72 g, 256 mmol) and 
triethylamine (36 mL, 256 mmol) in DCM (400 mL). The mixture was stirred at 20 °C for 3 d. The mixture 
was concentrated to 75% of the initial volume. The reaction mixture was quenched with water (200 mL), 
extracted with diethylether/heptane (1:1) (2 x 1 L), the organic layer was dried over MgSO4, filtered and 
evaporated. The crude product was purified by flash silica chromatography, elution gradient 10-30% 
EtOAc in heptane to afford the title compound (39 g, 66%) as a white crystalline solid.  1H NMR (400 
MHz, DMSO-d6, 100 °C) δ 1.28 (s, 9H), 1.88-2 (m, 1H), 2.15 (ddd, J = 6.2, 8.3, 14.2 Hz, 1H), 2.98 (dd, 
J = 4.4, 11.2 Hz, 1H), 3.13-3.2 (m, 1H), 3.28 (dd, J = 4.6, 8.4 Hz, 1H), 3.54 (dd, J = 5.9, 11.2 Hz, 1H), 
3.90 (tt, J = 4.5, 8.5 Hz, 1H), 4.13-4.21 (m, 1H), 4.54 (d, J = 4.0 Hz, 1H), 7.19-7.26 (m, 3H), 7.26-7.34 
(m, 6H), 7.37 (dt, J = 1.9, 8.4 Hz, 6H); HRMS (ES+) for C29H33NO4 (M+Na)
+: calcd, 482.2307; found, 
482.2296. 
tert-Butyl (2S,4S)-4-(((E)-4-bromobut-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-
carboxylate (46) 
 50% Sodium hydroxide solution (10 mL) was added to a vigrously stirred solution of tert-butyl (2S,4S)-
4-hydroxy-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (2.06 g, 4.48 mmol), (E)-1,4-dibromobut-2-
ene (4.31 g, 20.2 mmol) and tetrabutylammonium hydrogensulfate (76 mg, 0.22 mmol) in toluene (30 
mL). The reaction mixture was stirred at rt for 18 h. The mixture was diluted with water (50 mL) and 
diethylether (150 mL). The organic phase was separated and washed with water (2 x 50 mL) and saturated 
brine (50 mL). The organic layer was dried over MgSO4, filtered and evaporated to afford a residue which 
was purified by flash silica chromatography, elution gradient 0 to 30% EtOAc in heptane to afford the 
title compound (1.72 g, 65%) as a colourless oil.  1H NMR (400 MHz, DMSO-d6) δ 1.30 (s, 9H), 2.03-
2.21 (m, 2H), 3.01-3.06 (m, 1H), 3.11 (dd, J = 2.8, 11.7 Hz, 1H), 3.30 (dd, J = 4.7, 8.3 Hz, 1H), 3.55 (dd, 
J = 5.7, 11.8 Hz, 1H), 3.83-3.89 (m, 2H), 3.91-4.08 (m, 4H), 5.71-5.81 (m, 2H), 7.17-7.45 (m, 15H). 13C 
NMR (101 MHz, CDCl3) δ 28.40, 31.90, 34.02, 51.88, 53.40, 56.26, 64.55, 68.21, 79.54, 86.34, 126.89, 
127.75, 128.02, 128.76, 131.70, 144.21, 154.38; HRMS (ES+) for C33H38NO4Br (M+Na)
+: calcd, 
614.1882; found, 614.1889. 
(2S,4S)-tert-Butyl 4-(((E)-4-((6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-en-1-yl)oxy)-
2-((trityloxy)methyl)pyrrolidine-1-carboxylate  (47) 
A mixture of 44 (2.0 g, 14.5 mmol), 46 (1.83 g, 3.09 mmol) and DMF (15 mL) was stirred at 80 °C for 
75 min. After cooling to rt the mixture was diluted with EtOAc (250 mL) and the solid was filtered off. 
The filtrate was washed with 1M citric acid (25 mL), water (2 x 25 mL) and saturated brine (25 mL). The 
organic layer was dried over Na2SO4, filtered and evaporated to afford a residue which was purified by 
flash silica chromatography, elution gradient 0 to 70% EtOAc in heptane to afford the title compound 
(2.14 g, 96%) as a pale yellow solid.  1H NMR (400 MHz, DMSO-d6, 100 °C) δ 1.31 (s, 9H), 2.23-2.04 
(m, 2H), 2.54-2.61 (m, 2H), 3.00-3.10 (m, 3H), 3.12 (ddd, J = 0.8, 3.5, 11.7 Hz, 1H), 3.32 (dd, J = 4.7, 
8.3 Hz, 1H), 3.58 (dd, J = 5.8, 11.7 Hz, 1H), 3.91 (dq, J = 1.3, 2.7 Hz, 2H), 3.98 (tt, J = 4.3, 8.1 Hz, 1H), 
4.04 (tt, J = 3.6, 5.7 Hz, 1H), 4.70-4.76 (m, 2H), 5.85-5.90 (m, 2H), 7.21-7.24 (m, 2H), 7.25 (t, J = 1.4 
Hz, 1H), 7.27-7.34 (m, 6H), 7.34-7.43 (m, 6H), 7.70 (d, J = 2.4 Hz, 1H), 7.78 (dd, J = 1.1, 2.3 Hz, 1H), 
9.10 (br s, 1H); 13C NMR (126 MHz, DMSO-d6, 100 °C) δ 25.17, 28.61, 30.33, 33.86, 52.50, 56.32, 65.17, 
 68.51, 69.87, 76.97, 79.04, 86.55, 107.27, 116.67, 125.16, 126.63, 127.29, 128.11, 128.77, 131.50, 
134.65, 142.51, 144.54, 144.97, 153.99, 169.85; HRMS (ES+) for C42H45N3O8 (M+Na)
+: calcd, 742.3099; 
found, 742.3098. 
(2S,4S)-tert-Butyl 4-(((E)-4-((6-amino-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-en-1-
yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate 
Iron powder (0.366 g, 6.56 mmol) was added to 47 (787 mg, 1.09 mmol) and ammonium chloride (41 
mg, 0.77 mmol) in EtOH (15 mL) and water (5 mL). The resulting mixture was stirred at 60 °C for 4 h. 
The reaction mixture was evaporated to dryness, redissolved in EtOAc (100 mL), and washed sequentially 
with water (2 x 100 mL) and saturated brine (100 mL). The organic layer was dried with MgSO4, filtered 
and evaporated to afford the title compound (727 mg, 96%) as a yellow foam.  1H NMR (400 MHz, 
DMSO-d6, 100 °C) δ 1.29 (s, 9H), 2.05-2.2 (m, 2H), 2.33-2.41 (m, 2H), 2.69-2.77 (m, 2H), 3.05 (t, J = 
8.1 Hz, 1H), 3.11 (dd, J = 3.2, 11.7 Hz, 1H), 3.30 (dd, J = 4.7, 8.3 Hz, 1H), 3.56 (dd, J = 5.7, 11.7 Hz, 
1H), 3.88 (d, J = 3.5 Hz, 2H), 3.96 (dq, J = 4.1, 4.5, 8.1 Hz, 1H), 4.02 (tt, J = 2.9, 5.8 Hz, 1H), 4.42-4.52 
(m, 4H), 5.72-5.86 (m, 2H), 6.06 (d, J = 1.6 Hz, 1H), 6.20 (d, J = 2.2 Hz, 1H), 7.18-7.25 (m, 3H), 7.26-
7.32 (m, 6H), 7.34-7.4 (m, 6H), 7.92 (s, 1H); HRMS (ES+) for C42H47O6N3 (M+H)
+: calcd, 690.3538; 
found, 690.3534. 
(13S,15S,26Z,7E)-15-(Hydroxymethyl)-42-oxo-41,42,43,44-tetrahydro-5,10-dioxa-3-aza-4(6,8)-
quinolina-2(5,7)-pyrazolo[1,5-a]pyrimidina-1(1,3)-pyrrolidinacyclodecaphan-7-ene-23-
carbonitrile (11) 
To (2S,4S)-tert-butyl 4-(((E)-4-((6-amino-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-en-1-
yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (0.242 g, 0.35 mmol) was added 37 (75 mg, 0.35 
mmol) and DIPEA (0.183 mL, 1.05 mmol) in EtOH (3.5 mL). The resulting mixture was stirred at 60 °C 
for 4 h and then evaporated to dryness. The residue was dissolved in DCM (3.5 mL) and TFA (3.5 mL) 
was added slowly. The mixture was stirred for 3 h and then evaporated to dryness. The residue was 
dissolved in DCM (3.5 mL) and added to DIPEA (1.83 mL, 10.5 mmol) and n-butanol (35 mL) at 130 
°C. The mixture was heated for 4 h and then cooled to rt. The reaction mixture was evaporated to dryness 
 and redissolved in EtOAc (25 mL), and washed sequentially with water (25 mL) and saturated brine (25 
mL). The organic layer was dried with MgSO4, filtered and evaporated to afford a residue which was 
purified by flash silica chromatography, elution gradient 0 to 5% MeOH in DCM to afford a yellow 
residue.   This was triturated with tert-butyl methylether to give a solid which was collected by filtration 
and dried under vacuum to give the title compound as a yellow powder (78 mg, 46%).  1H NMR (400 
MHz, DMSO-d6) δ 2.11-2.18 (m, 2H), 2.44-2.47 (m, 1H), 2.85 (hept, J = 7.3, 7.8 Hz, 2H), 3.16 (dd, J = 
3.2, 11.7 Hz, 1H), 3.35-3.43 (m, 1H), 3.86 (d, J = 11.8 Hz, 1H), 3.93 (dd, J = 8.7, 15.3 Hz, 1H), 4.08-
4.18 (m, 3H), 4.3-4.38 (m, 1H), 4.6-4.69 (m, 1H), 4.84 (dd, J = 4.0, 6.6 Hz, 1H), 4.93 (dd, J = 8.7, 15.1 
Hz, 1H), 5.65-5.79 (m, 3H), 5.92 (dt, J = 9.8, 16.2 Hz, 1H), 6.72 (d, J = 1.5 Hz, 1H), 7.19 (d, J = 1.9 Hz, 
1H), 8.35 (s, 1H), 9.04 (s, 1H), 9.70 (s, 1H); 13C NMR (126 MHz, DMSO-d6) δ 25.03, 30.45, 34.65, 53.06, 
58.72, 61.89, 66.40, 70.05, 75.38, 76.80, 79.22, 105.72, 115.09, 115.69, 124.81, 125.49, 127.92, 131.93, 
134.00, 144.21, 145.39, 145.95, 151.62, 157.20, 169.45; HRMS (ES+) for C25H25N7O4 (M+H)
+: calcd, 
488.2046; found, 488.2045; [α]24D -68.9 (c 2.1, CHCl3).   
tert-Butyl (2S,4S)-4-(((E)-4-((1-benzyl-6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-en-
1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (61, R4 = Bn) 
Benzyl bromide (0.147 mL, 1.24 mmol) was added to a stirred solution of 47 (850 mg, 1.18 mmol) and 
cesium carbonate (380 mg, 1.17 mmol) in DMF (8 mL). The mixture was stirred at 80 °C for 30 min. The 
reaction mixture was evaporated to dryness and redissolved in EtOAc (100 mL), and washed sequentially 
with water (2 x 50 mL) and saturated brine (50 mL). The organic layer was dried with MgSO4, filtered 
and evaporated to afford a residue which was purified by flash silica chromatography, elution gradient 0 
to 60% EtOAc in heptane to afford the title compound (733 mg, 77%) as a yellow solid.  1H NMR (400 
MHz, DMSO-d6, 100 °C) δ 1.29 (s, 9H), 2.03-2.19 (m, 2H), 2.59-2.64 (m, 2H), 2.94-2.99 (m, 2H), 3.06 
(t, J = 8.1 Hz, 1H), 3.10 (dd, J = 3.5, 11.8 Hz, 1H), 3.30 (dd, J = 4.6, 8.3 Hz, 1H), 3.56 (dd, J = 5.8, 11.7 
Hz, 1H), 3.83 (d, J = 4.6 Hz, 2H), 3.9-4.04 (m, 2H), 4.53-4.64 (m, 2H), 5.28 (s, 2H), 5.57-5.66 (m, 1H), 
5.71-5.8 (m, 1H), 7.03-7.12 (m, 3H), 7.14-7.24 (m, 5H), 7.24-7.32 (m, 6H), 7.33-7.41 (m, 6H), 7.65 (d, J 
= 2.5 Hz, 1H), 7.75 (d, J = 2.5 Hz, 1H); 13C NMR (101 MHz, DMSO-d6, 100 °C) δ 25.88, 28.61, 32.05, 
 33.88, 47.58, 52.51, 56.33, 65.15, 68.43, 69.97, 76.98, 79.06, 86.56, 108.64, 115.82, 126.14, 126.99, 
127.06, 127.30, 128.11, 128.48, 128.79, 132.10, 133.21, 136.01, 138.67, 143.98, 144.56, 148.82, 154.02, 
171.61; HRMS (ES+) for C49H51N3O8 (M+Na)
+: calcd, 832.3568; found, 832.3569. 
tert-Butyl (2S,4S)-4-(((E)-4-((6-amino-1-benzyl-2-oxo-1,2,3,4-tetrahydroquinolin-8-yl)oxy)but-2-
en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (62, R4 = Bn) 
Iron powder (397 mg, 7.11 mmol) was added to a stirred mixture of 61 (R4 = Bn) (720 mg, 0.89 mmol), 
ammonium chloride (221 mg, 4.13 mmol), THF (10 mL), MeOH (10 mL) and water (4 mL). The resulting 
mixture was stirred at 70 °C for 60 min, cooled, diluted with EtOAc (125 mL), and washed sequentially 
with water (50 mL) and saturated brine (50 mL). The organic layer was dried with MgSO4, filtered and 
evaporated to afford a residue which was purified by flash silica chromatography, elution gradient 30 to 
70% EtOAc in heptane to afford the title compound (547 mg, 79%) as a yellow solid.  1H NMR (400 
MHz, DMSO-d6, 100 °C) δ 1.29 (s, 9H), 2.04-2.2 (m, 2H), 2.39-2.45 (m, 2H), 2.60 (dd, J = 5.3, 8.2 Hz, 
2H), 3.06 (t, J = 8.1 Hz, 1H), 3.11 (dd, J = 3.2, 11.7 Hz, 1H), 3.31 (dd, J = 4.7, 8.3 Hz, 1H), 3.56 (dd, J 
= 5.8, 11.7 Hz, 1H), 3.84 (d, J = 4.7 Hz, 2H), 3.9-4.05 (m, 2H), 4.36 (d, J = 4.6 Hz, 2H), 4.60 (s, 2H), 
5.16 (s, 2H), 5.59-5.75 (m, 2H), 6.05 (d, J = 2.3 Hz, 1H), 6.13 (d, J = 2.3 Hz, 1H), 7.01-7.11 (m, 3H), 
7.11-7.18 (m, 2H), 7.18-7.24 (m, 3H), 7.25-7.32 (m, 6H), 7.33-7.42 (m, 6H); HRMS (ES+) for C49H53N3O6 
(M+H)+: calcd, 780.4013; found, 780.4017. 
(13S,15S,26Z,7E)-41-Benzyl-23-chloro-15-(hydroxymethyl)-41,42,43,44-tetrahydro-5,10-dioxa-3-
aza-4(6,8)-quinolina-2(5,7)-pyrazolo[1,5-a]pyrimidina-1(1,3)-pyrrolidinacyclodecaphan-7-en-42-
one (31) 
3,5,7-Trichloropyrazolo[1,5-a]pyrimidine (48) (78 mg, 0.35 mmol) was added to a stirred solution of 62 
(R4 = Bn) (273 mg, 0.35 mmol) and DIPEA (0.1 mL, 0.57 mmol) in EtOH (5 mL). The reaction mixture 
was stirred at 80 °C for 2.5 h. After cooling to rt, 4M HCl in 1,4-dioxane (5 mL, 20 mmol) was added and 
the mixture was stirred at rt for 1 h. The mixture was evaporated to dryness to afford the uncyclized 
product as gum which was transferred into a microwave vial and n-butanol (20 mL) and DIPEA (0.6 mL, 
3.44 mmol) were added. The mixture was stirred at 140 °C within the microwave reactor for 3 h and 
 cooled to rt. The solvent was evaporated in vacuo to yield crude product which was purified by preparative 
HPLC (Waters XSelect CSH C18 column, 5µ silica, 30 mm diameter, 100 mm length), using decreasingly 
polar mixtures of water (containing 1% NH3) and acetonitrile as eluents to afford the title compound (36 
mg, 18%) as a tan solid.  1H NMR (500 MHz, DMSO-d6) δ 2.02 (d, J = 12.6 Hz, 1H), 2.18 (ddt, J = 4.6, 
9.2, 13.8 Hz, 1H), 2.57 (t, J = 7.4 Hz, 2H), 2.74-2.87 (m, 2H), 3.12 (dd, J = 3.2, 11.3 Hz, 1H), 3.35-3.44 
(m, 1H), 3.81 (d, J = 11.6 Hz, 1H), 3.86 (dd, J = 9.4, 15.8 Hz, 2H), 4-4.14 (m, 3H), 4.27-4.35 (m, 1H), 
4.44-4.52 (m, 1H), 4.79 (dd, J = 8.9, 15.1 Hz, 1H), 5.17-5.26 (m, 2H), 5.27 (dd, J = 3.6, 7.5 Hz, 1H), 
5.59 (dd, J = 8.6, 15.9 Hz, 1H), 5.86 (dd, J = 8.7, 16.1 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 7.09-7.18 (m, 
4H), 7.19-7.26 (m, 2H), 7.98 (s, 1H), 9.57 (s, 1H); 13C NMR (101 MHz, CDCl3) δ 26.58, 32.62, 38.37, 
48.25, 53.79, 61.44, 67.12, 69.24, 71.20, 76.37, 79.17, 94.68, 104.78, 114.64, 126.56, 126.65, 126.98, 
127.32, 128.13, 133.29, 133.54, 133.82, 138.89, 141.51, 144.21, 144.39, 148.58, 156.28, 172.01; HRMS 
(ES+) for C31H31ClN6O4 (M+H)
+: calcd, 587.2174; found, 587.2159; [α]25D -81.3 (c 0.56, CHCl3). 
tert-Butyl (2S,4S)-4-(((E)-4-((1-(3-methoxybenzyl)-6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-8-
yl)oxy)but-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (61, R4 = m-MeO-Bn) 
1-(Bromomethyl)-3-methoxybenzene (0.128 mL, 0.91 mmol) was added to a stirred solution of 47 (626 
mg, 0.87 mmol) and cesium carbonate (283 mg, 0.87 mmol) in DMF (8 mL). The mixture was stirred at 
80 °C for 30 min. The reaction mixture was evaporated to dryness and redissolved in EtOAc (20 mL) and 
washed sequentially with water (2 x 20 mL) and saturated brine (20 mL). The organic layer was dried 
with MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash 
silica chromatography, elution gradient 0 to 60% EtOAc in heptane to afford the title compound (550 mg, 
75%) as a yellow solid.  1H NMR (500 MHz, CDCl3) δ 1.29 (s, 9H), 2.13-2.24 (m, 1H), 2.32-2.41 (m, 
1H), 2.66-2.75 (m, 2H), 2.9-2.99 (m, 2H), 3.05-3.17 (m, 1H), 3.28 (dd, J = 3.5, 11.8 Hz, 1H), 3.35-3.44 
(m, 1H), 3.62-3.68 (m, 1H), 3.69 (s, 3H), 3.85 (d, J = 5.1 Hz, 2H), 4.02 (s, 2H), 4.50 (d, J = 5.6 Hz, 2H), 
5.36 (s, 2H), 5.57-5.68 (m, 1H), 5.75 (dt, J = 5.3, 15.7 Hz, 1H), 6.57-6.71 (m, 3H), 7.09 (t, J = 7.9 Hz, 
1H), 7.20 (t, J = 7.3 Hz, 3H), 7.23-7.3 (m, 6H), 7.43 (d, J = 7.7 Hz, 6H), 7.60 (d, J = 2.5 Hz, 1H), 7.71 
(d, J = 2.5 Hz, 1H); MS (ESI) [M + Na]+ m/z 862.  
 tert-Butyl (2S,4S)-4-(((E)-4-((6-amino-1-(3-methoxybenzyl)-2-oxo-1,2,3,4-tetrahydroquinolin-8-
yl)oxy)but-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (62, R4 = m-MeO-Bn) 
Iron powder (286 mg, 5.12 mmol) was added to a stirred mixture of 61 (R4 = m-MeO-Bn) (538 mg, 0.64 
mmol), ammonium chloride (221 mg, 4.13 mmol), THF (8 mL), MeOH (8 mL) and water (4 mL). The 
resulting mixture was stirred at 70 °C for 60 min. The reaction mixture was diluted with EtOAc (125 mL) 
and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried 
with MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash 
silica chromatography, elution gradient 40 to 70% EtOAc in heptane to afford the title compound (430 
mg, 83%) as a yellow gum.  1H NMR (500 MHz, CDCl3) δ 1.29 (s, 6H), 1.44 (s, 3H), 2.12-2.22 (m, 1H), 
2.3-2.38 (m, 1H), 2.56-2.61 (m, 2H), 2.68-2.74 (m, 2H), 3.06-3.17 (m, 1H), 3.27 (dd, J = 3.3, 11.8 Hz, 
1H), 3.38 (dd, J = 4.1, 7.9 Hz, 1H), 3.49-3.57 (m, 2H), 3.63-3.69 (m, 4H), 3.8-3.88 (m, 2H), 3.97-4.06 
(m, 2H), 4.34-4.38 (m, 2H), 5.25 (s, 2H), 5.56-5.71 (m, 2H), 6.05 (d, J = 2.4 Hz, 1H), 6.10 (d, J = 2.4 
Hz, 1H), 6.64-6.67 (m, 2H), 6.68-6.71 (m, 1H), 7.04-7.1 (m, 1H), 7.20 (t, J = 7.3 Hz, 3H), 7.24-7.29 (m, 
6H), 7.43 (d, J = 7.5 Hz, 6H); MS (ESI) [M-H]- m/z 808.  
(13S,15S,26Z,7E)-23-Chloro-15-(hydroxymethyl)-41-(3-methoxybenzyl)-41,42,43,44-tetrahydro-
5,10-dioxa-3-aza-4(6,8)-quinolina-2(5,7)-pyrazolo[1,5-a]pyrimidina-1(1,3)-
pyrrolidinacyclodecaphan-7-en-42-one (32) 
3,5,7-Trichloropyrazolo[1,5-a]pyrimidine (48) (119 mg, 0.53 mmol) was added to a stirred solution of 62 
(R4 = m-MeO-Bn) (432 mg, 0.53 mmol) and DIPEA (0.15 mL, 0.86 mmol) in EtOH (5 mL). The reaction 
mixture was stirred at 80 °C for 2.5 h. After cooling to rt, 4M HCl in 1,4-dioxane (8 mL, 32 mmol) was 
added. The mixture was stirred at rt for 60 min then evaporated to dryness to afford the uncyclized 
intermediate as a gum, which was transferred into a microwave vial and n-butanol (20 mL) and DIPEA 
(0.9 mL, 5.15 mmol) were added. The mixture was stirred at 140 °C within the microwave reactor for 3 
h and cooled to rt. The solvent was evaporated in vacuo to yield crude product which was purified by 
preparative HPLC (Waters XSelect CSH C18 column, 5µ silica, 30 mm diameter, 100 mm length), using 
decreasingly polar mixtures of water (containing 1% NH3) and acetonitrile as eluents to afford the title 
 compound (137 mg, 42%) as a tan solid.  1H NMR (500 MHz, CDCl3) δ 1.91 (d, J = 14.0 Hz, 1H), 2.44 
(ddd, J = 4.6, 10.3, 14.6 Hz, 1H), 2.64-2.75 (m, 2H), 2.8-2.94 (m, 2H), 3.14 (dd, J = 2.8, 11.4 Hz, 1H), 
3.73 (s, 3H), 3.76-3.94 (m, 3H), 3.98-4.09 (m, 2H), 4.33-4.4 (m, 1H), 4.44-4.55 (m, 2H), 4.57-4.65 (m, 
1H), 5.31 (s, 2H), 5.52-5.6 (m, 1H), 5.71 (s, 1H), 5.82-5.91 (m, 1H), 6.50 (s, 1H), 6.61 (d, J = 2.0 Hz, 
1H), 6.67-6.77 (m, 3H), 6.96 (d, J = 2.0 Hz, 1H), 7.16 (t, J = 7.8 Hz, 1H), 7.49 (s, 1H), 7.76 (s, 1H); 13C 
NMR (101 MHz, CDCl3) δ 26.58, 32.61, 38.37, 47.97, 53.79, 55.15, 61.45, 67.11, 69.24, 71.20, 76.38, 
79.17, 94.61, 104.84, 111.70, 112.79, 114.68, 119.13, 126.90, 127.35, 129.15, 133.33, 133.60, 133.80, 
140.50, 141.50, 144.24, 144.47, 148.57, 156.30, 159.56, 172.01; HRMS (ES+) for C32H33ClN6O5 (M+H)
+: 
calcd, 617.2279; found, 617.2300; [α]25D -73.2 (c 2.01, CHCl3). 
tert-Butyl (2S,4S)-4-(((E)-4-((1-(2-methylbenzyl)-6-nitro-2-oxo-1,2,3,4-tetrahydroquinolin-8-
yl)oxy)but-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (61, R4 = o-Me-Bn) 
1-(Bromomethyl)-2-methylbenzene (0.158 mL, 1.18 mmol) was added to a stirred solution of 47 (532 
mg, 1.12 mmol) and cesium carbonate (365 mg, 1.12 mmol) in DMF (8 mL). The mixture was stirred at 
80 °C for 30 min. The reaction mixture was evaporated to dryness and redissolved in EtOAc (20 mL) and 
washed sequentially with water (2 x 20 mL) and saturated brine (20 mL). The organic layer was dried 
with MgSO4, filtered and evaporated to afford crude product. The crude product was purified by flash 
silica chromatography, elution gradient 0 to 60% EtOAc in heptane to afford the title compound (557 mg, 
60%) as a yellow solid.  1H NMR (500 MHz, CDCl3) δ 1.28 (d, J = 11.8 Hz, 9H), 2.17 (s, 1H), 2.22 (s, 
3H), 2.34 (d, J = 13.5 Hz, 1H), 2.69-2.77 (m, 2H), 3.01 (dd, J = 5.5, 8.5 Hz, 2H), 3.08 (t, J = 8.4 Hz, 
1H), 3.27 (dd, J = 3.6, 11.7 Hz, 1H), 3.38 (d, J = 6.6 Hz, 1H), 3.6-3.69 (m, 1H), 3.74 (d, J = 5.4 Hz, 2H), 
4.00 (d, J = 31.3 Hz, 2H), 4.34-4.41 (m, 2H), 5.21 (s, 3H), 5.57 (dt, J = 5.5, 15.7 Hz, 1H), 6.89 (d, J = 
7.3 Hz, 1H), 7.02 (dd, J = 5.1, 7.7 Hz, 1H), 7.04-7.08 (m, 2H), 7.20 (t, J = 7.3 Hz, 3H), 7.23-7.31 (m, 
6H), 7.42 (d, J = 7.6 Hz, 6H), 7.61 (d, J = 2.5 Hz, 1H), 7.75 (d, J = 2.5 Hz, 1H); MS (ESI) [M+formic-
H]- m/z 868. 
tert-Butyl (2S,4S)-4-(((E)-4-((6-amino-1-(2-methylbenzyl)-2-oxo-1,2,3,4-tetrahydroquinolin-8-
yl)oxy)but-2-en-1-yl)oxy)-2-((trityloxy)methyl)pyrrolidine-1-carboxylate (62, R4 = o-Me-Bn) 
 Iron powder (302 mg, 5.41 mmol) was added to a stirred mixture of 61 (R4 = o-Me-Bn) (557 mg, 0.68 
mmol), ammonium chloride (325 mg, 6.08 mmol), THF (4 mL), MeOH (4 mL) and water (2 mL). The 
resulting mixture was stirred at 70 °C for 60 min. The reaction mixture was diluted with EtOAc (125 mL), 
and washed sequentially with water (50 mL) and saturated brine (50 mL). The organic layer was dried 
with MgSO4, filtered and evaporated to afford the crude title compound (501 mg, 93%) as a yellow solid 
which was used without further purification. MS (ESI) [M + Na]+ m/z 816. 
(13S,15S,26Z,7E)-23-Chloro-15-(hydroxymethyl)-41-(2-methylbenzyl)-41,42,43,44-tetrahydro-
5,10-dioxa-3-aza-4(6,8)-quinolina-2(5,7)-pyrazolo[1,5-a]pyrimidina-1(1,3)-
pyrrolidinacyclodecaphan-7-en-42-one (34) 
3,5,7-Trichloropyrazolo[1,5-a]pyrimidine (48) (63.3 mg, 0.28 mmol) was added to a stirred solution of 
62 (R4 = o-Me-Bn) (226 mg, 0.28 mmol) and DIPEA (0.099 mL, 0.57 mmol) in EtOH (5 mL). The 
reaction mixture was stirred at 80 °C for 2.5 h and then EtOH was evaporated. The reaction mixture was 
redissolved in 1,4-dioxane (2 mL), 4M HCl in 1,4-dioxane (3.6 mL, 14.2 mmol) was added and the 
reaction was stirred at rt for 1 h. The mixture was evaporated to dryness to afford the intermediate product 
as gum which was transferred into a microwave vial and n-butanol (5 mL) and DIPEA (0.15 mL, 0.85 
mmol) was added. The mixture was stirred at 140 °C within the microwave reactor for 2 h and cooled to 
rt. The solvent was evaporated in vacuum to yield crude product. The crude product was purified by 
preparative HPLC (Waters XSelect CSH C18 column, 5µ silica, 30 mm diameter, 100 mm length), using 
decreasingly polar mixtures of water (containing 1% NH3) and acetonitrile as eluents, then further purified 
by flash silica chromatography, elution gradient 1 to 5% MeOH in DCM to afford the title compound (32 
mg, 19%) as a colourless gum.  1H NMR (500 MHz, CDCl3) δ 1.79-1.88 (m, 1H), 2.26 (s, 3H), 2.36 (ddd, 
J = 4.7, 10.3, 14.0 Hz, 1H), 2.58-2.75 (m, 2H), 2.79-2.95 (m, 2H), 3.05 (dd, J = 3.0, 11.4 Hz, 1H), 3.66 
(dd, J = 9.1, 15.2 Hz, 1H), 3.73-3.86 (m, 2H), 3.91 (dd, J = 2.0, 11.5 Hz, 1H), 3.97 (d, J = 3.9 Hz, 1H), 
4.19-4.46 (m, 4H), 5.12 (d, J = 16.2 Hz, 1H), 5.15-5.27 (m, 2H), 5.61 (s, 1H), 5.64-5.82 (m, 1H), 6.43 (d, 
J = 8.6 Hz, 1H), 6.58 (d, J = 2.3 Hz, 1H), 6.81-6.95 (m, 2H), 6.94-7.12 (m, 3H), 7.47 (s, 1H), 7.69 (s, 
1H); 13C NMR (101 MHz, CDCl3) δ 19.22, 26.61, 32.57, 38.34, 46.64, 53.79, 61.42, 66.99, 69.20, 71.15, 
 76.33, 79.14, 94.60, 105.11, 114.94, 125.41, 125.56, 126.11, 127.15, 127.40, 129.96, 133.22, 133.36, 
133.44, 134.48, 136.82, 141.49, 144.19, 144.61, 148.37, 156.27, 171.91; HRMS (ES+) for C32H33ClN6O4 
(M+H)+: calcd, 601.2330; found, 601.2332; [α]25D -65.5 (c 2.05, CHCl3). 
 
Biological Protocols: 
 
Cloning, expression and purification of human BCL6 BTB domain 
The gene sequence encoding BCL6 BTB domain (5-129)13 was customer-synthesized with N-terminal 
His6 and thrombin protease cleavage site (Life Technologies, Carlsbad, CA). The synthetic gene was 
cloned into pET28b(+) (Novagen Biosciences, Madison, WI) to create plasmid pAZB1279.  To reduce 
oxidation and aggregation, the mutations of C8Q, C57R and C84N were introduced during gene synthesis. 
The final construct was confirmed by sequencing, and the protein matched that of  BCL6 BTB domain 
(Uniprot accession number P41182; residues 5-129 with the mutations of C8Q, C57R and C84N).  This 
material was used in the FRET assay. 
For structural studies, the same gene sequence encoding BCL6 BTB domain as pAZB1279 was 
customer-synthesized with N-terminal Thioredoxin-His6, TEV protease cleavage site, AVI tag and 
thrombin cleavage site (Life Technologies, Carlsbad, CA). The synthetic gene was cloned into pET32a(+) 
(Novagen Biosciences, Madison, WI) to create plasmid pAZB1280. The final construct was confirmed 
by sequencing, and the protein matched that of  BCL6 BTB domain (Uniprot accession number P41182; 
residues 5-129 with the mutations of C8Q, C57R and C84N).  The plasmid was transformed into E. coli 
BL21(DE3) (Agilent Technologies). A single colony was inoculated into a 100 mL culture of LB 
containing 50 μg/ml kanamycin and grown overnight at 37 °C.  The overnight culture was diluted to 
OD600=0.1 in 2 x 1-liter of LB containing 50 μg/ml kanamycin and grown at 30 °C with aeration to mid-
logarithmic phase (OD600 = 0.6). The culture was incubated on ice for 30 min and transferred to 16 °C. 
IPTG was then added to a final concentration in each culture of 0.5 mM.  The frozen cell paste from 6 L 
of cell culture was suspended in 50 mL of buffer A consisting of 25 mM Tris/HCl, pH 8.0, 0.5 M NaCl, 
 5% (v/v) glycerol, supplemented with 1 EDTA-free protease inhibitor cocktail tablet (Roche Molecular 
Biochemical, Indianapolis, IN). Cells were disrupted by French pressure at 18,000 psi twice at 4 ºC, and 
the crude extract was centrifuged at 150,000 g (45Ti rotor, Bechman-Coulter, Brea, CA) for 30 min at 4 
ºC. The supernatant was applied at a flow rate of 2.0 mL/min onto a 5-ml HiTrap Ni2+ chelating column 
(GE Healthcare Life Sciences, Piscataway, NJ) pre-equilibrated with buffer A. The column was then 
washed with buffer A, and BCL6 was eluted by a linear gradient from 0 M to 0.5 M imidazole in buffer 
A. Fractions containing BCL6 were pooled, and the thioredoxin tag of BCL6 fusion protein was removed 
by thrombin protease. The BCL6 sample was applied at a flow rate of 1.5 mL/min to a 120-mL Superdex 
200 (HR 16/60) (GE Healthcare Life Sciences) pre-equilibrated with buffer B consisting of 25 mM 
Tris/HCl, pH 8.5, 0.45 M NaCl, 1 mM TCEP, 10% (v/v) glycerol. The fractions containing BCL6 were 
pooled and concentrated by Amicon® Ultracel-10K (Millipore). The protein concentration was 
determined by Bradford method and characterized by SDS-PAGE analysis and analytical LC-MS. The 
protein was stored at -80 ºC. For X-ray crystallography studies, the tag of BCL6 fusion protein was 
removed by thrombin protease. 
 
15N-labeled BCL6 BTB domain: pAZB1280 was transformed into E. coli BL21 (Novagen, Madison WI) 
and plated on LB agar containing 50 μg/ml kanamycin and grown overnight at 37°C. Uniformly 15N-
labeled protein was prepared by innoculating transformants from the above-described plate into M9 
minimal media containing 50 μg/mL kanamycin and supplemented with 1 g/L [15N] NH4Cl and 10 g/L 
glucose as the sole nitrogen and carbon sources.  After growing at 37 °C with aeration to mid-logarithmic 
phase (OD600 = 0.6), IPTG was added to a final concentration of 0.5 mM to induce expression.   After 22 
h at 16 °C, the cells were harvested by centrifugation at 5,000 x g for 15 min at 25 °C. The purification 
protocol was the same as non-labeled BCL6. 
 
BCL6 SPR assay: 
 Biacore 4000 or T200 instruments (GE Healthcare) were used to monitor binding interactions via SPR. 
H6-BCL6 (5-129) was immobilized using NTA capture-coupling at a flow rate of 10 μL/min in buffer 
containing 10 mM HEPES, 1 mM TCEP and 0.005% Tween-20, pH 7.5 at 25 °C. The sensor surface was 
activated with a 1 min injection of 0.5 mM NiCl2 and a 7 min injection of 50 mM N-hydroxysuccinimide 
with 200 mM 1-ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride. 50 g/mL of BCL6 
protein was injected for 1 min. and the surface blocked with 1M ethanolamine, pH 8.5. Reference flow 
cells were prepared without protein. All binding measurements were performed in 25 mM HEPES, 150 
mM NaCl, 1 mM TCEP, 0.005% (v/v) Tween-20, 2% DMSO, pH7.5 at 25 °C.  Prior to analysis, solvent 
calibration and double referencing subtractions were made to eliminate bulk refractive index changes, 
injection noise and data drift. Affinity and binding kinetic parameters were determined by global fitting 
to a 1:1 binding model within the Biacore Evaluation Software (GE Healthcare). 
 
BCL6 2D NMR assay 
NMR spectra were acquired at 300 K with a 600 MHz NMR instrument (Bruker, Billerica MA) equipped 
with an AVANCE III console and a triple-resonance cryogenic probe. Samples were at pH 7.0 in a 50 
mM sodium phosphate buffer containing 400 mM sodium chloride, and 5% deuterium oxide. The 
concentration of 15N labeled BCL6 was 0.09 mM. Two-dimensional [15N, 1H] transverse relaxation 
optimized spectroscopy (TROSY) experiments were recorded with increasing ligand concentration.25 
Evolution times were approximately 53 ms in the 1H dimension and 29 ms in the 15N dimension. The total 
acquisition time was 28 min per experiment. 
 
BCL6 FRET assay 
Compound binding to BCL6 was determined by a time resolved fluorescence resonance energy transfer 
assay.  Assays were performed with 0.67 nM His BCL6 (5-129) C8Q, C67R & C84N,  0.125 nM Eu-
labeled anti His Antibody (Perkin Elmer, Waltham, MA) and 30 nM Hilyte 647 SMRT2 peptide (1414-
1430) H1426W12 (Anaspec, Freemont, CA) in 40 mM Hepes pH 7, 50 mM NaCl, 0.005% Tween-20, 0.5 
 mM TCEP buffer.  His tagged BCL6 (5-129) was mixed with Eu-anti-His antibody and added to white 
assay ready plates containing compound for a final assay concentration range of 100 uM to 0.33 nM in 
1% DMSO.  Assay plates contained maximum signal controls (1% DMSO final) and minimum signal 
controls (50 nM unlabeled SMRT2 peptide 1414-1430 with H1426W mutation).  BCL6, antibody and 
compound were incubated at rt for 30 min.  The binding reaction was initiated by addition of Hilyte 647 
SMRT2 peptide.  After 60 min at rt fluorescence was measured with a Tecan M1000 plate reader using 
an excitation wavelength of 340 nm and emission wavelengths of 612 nm and 665 nm.   
 
BCL6 and PLZF cell reporter assay 
HEK 293T/17 cells were transfected using Lipfectamine 3000 (Invitrogen) with a luciferase reporter 
vector containing yeast GAL4 binding sites and a thymidine kinase (TK) promotor, (GAL4)5TK-Luc.  
Cells were also transfected with 160 ng/ml of plasmid expressing a GAL4 DNA binding domain fused to 
BCL6BTB. Alternatively cell were transfected with 400 ng/mL plasmid expressing GAL4 DNA binding 
domain fused to PLZFBTB.  Plasmids were obtained through licensing agreements from the laboratory of 
Ari Melnick (Cornell Center for Technology). After transfection, cells were immediately distributed to 
384 well plates at a density of 10,000 cells/well. Cells were incubated for 24 h and then treated in triplicate 
with multiple concentrations of inhibitor or DMSO. After additional 24 h incubation, cells were examined 
for luciferase activity using Bright-Glo luciferase assay system (Promega, Madison, WI).  IC50 values 
were determined relative to luciferase activity of reference compound 11 at 8 μM, which compares to 
luciferase signal of (GAL4)5TK-Luc alone. 
 
DLBCL/AML cell proliferation assays 
Cells in their culture medium were directly dosed into 384-well flat bottom white microplates (Greiner, 
Monroe, NC) containing DMSO or multiple concentrations of compound (day 0), and then returned to 
the incubator for 72 h (day 3).  Cell density was pre-determined for each cell line based on linear phase 
growth over a 96 h period.  The number of viable cells on day 0 and 3 was determined using CellTiter-
 Glo (Promega, Madison, WI). Quantification of signal was determined using a Tecan Infinite F500 
(Männedorf, Switzerland). Percentage of net growth at day 3 (100%) relative to day 0 (0%) was calculated 
and the concentration of compound required to inhibit growth by 50% (GI50) determined. The assays were 
conducted in duplicate across different plates. 
 
Cell culture 
All cell lines were obtained from ATCC (Manassas, VA) or DSMZ (Braunschweig, Germany) unless 
otherwise specified. OCI-Ly1 and TMD8 cells were obtained from Mark Minden (Ontario Cancer 
Institute) and Shuji Tohda (Tokyo Medical and Dental University), respectively, and OCI-Ly3 and OCI-
Ly10 cells were obtained from Louis Staudt (National Cancer Institute).  Cells were maintained under 37 
°C humidified atmosphere containing 5% CO2 in specified media supplemented with 2 mM L-glutamine.  
SUDHL2, SUDHL4, and U-2932 were grown in RPMI1640 medium with 10% fetal bovine serum (FBS), 
Karpas 422 with 15% FBS, and AMO-1 with 20% FBS.  TMD8 and OCI-Ly19 were grown in α-MEM 
medium with 10% FBS and OCI-Ly1, OCI-Ly3, and OCI-Ly10 were grown in IMDM medium with 20% 
FBS and 50uM 2-mercaptoethanol.  HEK 293T/17 cells were grown in DMEM with 10% FBS. All 
medium and supplements were from Invitrogen (Carlsbad, CA), whereas FBS was from Sigma (St. Louis, 
MO).   
 
  
  
Supporting Information. Preparation and additional characterization for final compounds; NMR 
conformational analysis for 8 and 11; effect of 31 in in vitro radioligand binding enzyme and functional 
assays; kinase selectivity data for 11 and 31; crystallization and structure determination for 1, 2, 7, 11, 
with BCL6 and 11 with CK2.  This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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respectively.  Authors will release the atomic coordinates and experimental data upon article publication. 
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